Aspirin is considered an aff ordable and widely available, if only modestly eff ective, thromboprophylactic for secondary stroke prevention. The two large randomised controlled trials of aspirin in acute ischaemic stroke reported that aspirin reduced the odds of early recurrent stroke at 2-4 weeks by about 12% (odds ratio [OR] 0·88, 95% CI 0·79-0·97) and the odds of death or dependency at the end of follow-up by about 5% (OR 0·95, 0·91-0·99).
1 The ten trials of aspirin for long-term secondary prevention in patients with previous transient ischaemic attack (TIA) or ischaemic stroke reported that aspirin reduced the risk of any recurrent stroke over 3 years by about 17% (relative risk [RR] 0·83, 95% CI 0·72-0·96). 2 However, non-randomised observational studies have suggested that urgent medical treatments, including aspirin, in acute TIA and mild ischaemic stroke reduce the risk of recurrent stroke by up to 80%. 3 In The Lancet, Peter Rothwell and colleagues 4 report fi ndings from an analysis of the individual patient data from all randomised controlled trials of aspirin after ischaemic stroke or TIA, giving fresh insights into the eff ect of aspirin on the timing and severity of recurrent stroke and challenging our understanding of the role of aspirin in secondary stroke prevention.
Rothwell and colleagues found that in the three trials of aspirin versus control in acute ischaemic stroke (n=40 531), the overall eff ect of aspirin was indeed modest. However, there was signifi cant heterogeneity according to baseline stroke severity (p het =0·014). Aspirin appeared far more eff ective in reducing the 14 day risk of recurrent ischaemic stroke in patients with mild (OR 0·51, 95% CI 0·34-0·75) and moderate (0·65, 0·44-0·98) neurological damage after stroke, than for those with severe defi cits (OR 1·10, 0·77-1·58). Also, the reduction in recurrent stroke among patients with mild and moderate stroke was as great as half to two-thirds within the fi rst 2-6 days.
Moreover, among the 12 trials of secondary prevention of stroke in 15 778 patients with TIA or ischaemic
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The HubBLe study can help establish realistic patient expectations and provide a framework for counselling patients. This study has been a trend setter in selecting patient-reported outcomes as the primary endpoint. In context, patient-reported outcomes are now widely used, although this development is recent. 10 Use of a patientcentric qualitative endpoint is underpinned by the highquality health economics model applied in HubBLe.
The role of HAL, which has become widely accepted as a safe intervention for grade II-III haemorrhoids, will need re-evaluation. However, HAL might fi nd a niche role as second-line treatment for patients who relapse following a course of RBL and do not wish to have excisional haemorrhoidectomy. stroke randomised to aspirin or control, aspirin reduced the 12 week risk of any stroke by half (hazard ratio 0·49, 95% CI 0·40-0·60), disabling or fatal ischaemic stroke by two-thirds (0·34, 0·25-0·46), and acute myocardial infarction by two-thirds (0·30, 0·17-0·52).
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The eff ect of aspirin was consistent among the trials and independent of patient characteristics, stroke aetiology, and aspirin dose. The eff ect of aspirin was however, greater in the fi rst 6 weeks after randomisation (indeed greatest in the fi rst 2 weeks) than the second 6 weeks, and attenuated further to be of limited long-term benefi t thereafter. Among seven trials of dipyridamole plus aspirin versus aspirin in 9437 patients, the addition of dipyridamole to aspirin had no eff ect on the risk or severity of recurrent ischaemic stroke within 12 weeks, but did reduce risk thereafter, particularly of disabling or fatal ischaemic stroke. 4 These results suggest that we might have underestimated the eff ect of aspirin in preventing early recurrent stroke and myocardial infarction after TIA and ischaemic stroke, overestimated the eff ect of aspirin in preventing long-term recurrent stroke, been unaware of the benefi ts of aspirin in reducing the severity of early recurrent ischaemic stroke, and underestimated the eff ect of dipyridamole in preventing long-term recurrent stroke. These results have implications for clinical practice.
First, patients with suspected TIA or ischaemic stroke require urgent assessment and intervention. These people have a high early risk and ongoing long-term risk of recurrent stroke and other vascular events unless the underlying cardiovascular cause and its potential consequences are appropriately treated. 3 Second, aspirin is the fi rst-line antithrombotic of choice and should be administered immediately. The benefi ts in reducing the risk and severity of early recurrent stroke are greater than previously recognised. The potential risks associated with administering aspirin before brain imaging to exclude intracerebral haemorrhage (ICH) are likely to be low because this is a rare cause of transient or mild focal neurological symptoms, and the few randomised trials of antithrombotic therapy in such patients, 1 or patients with intracerebral haemorrhage, 5 have not reported adverse outcomes. However, a larger body of observational evidence suggests that antiplatelet therapy at the time of intracerebral haemorrhage might increase mortality. 6 Hence, caution and further research are warranted in this setting. Similarly, although observational studies suggest no detrimental eff ect of prior antiplatelet use in patients with ischaemic stroke who subsequently require thrombolysis, 7 further research is required. The implications of these results for public education are to raise awareness of the nature of the symptoms and signs of TIA and stroke, the high risk of early recurrent stroke even if symptoms have subsided, and the need to seek medical attention immediately. For individuals with stroke-like symptoms that are transient and resolve within minutes to an hour or so, self-administration of aspirin, while awaiting medical assessment, is likely to be safe and of benefi t in preventing a recurrent ischaemic event of the brain. For individuals with persistent strokelike symptoms that could possibly be due to intracerebral haemorrhage, the overall benefi ts of self-administration of aspirin are also likely to off set the risks, but further evaluation of such a public policy is recommended.
Rothwell and colleagues are now reviewing the individual patient data from other trials of antiplatelet therapy and will shortly report on factors that could modify the eff ects of antiplatelet drugs, and the longterm benefi ts, risks, and costs of continuing versus stopping specifi c antiplatelet drugs in patient subgroups. Meanwhile, the quest continues to identify antiplatelet and anticoagulant regimens that are even more eff ective than aspirin in preventing recurrent stroke, and their optimum timing and duration. Although there is no signifi cant benefi t of early ticagrelor compared with aspirin, 8 the early short-term use of clopidogrel and aspirin in combination is more eff ective than aspirin monotherapy in select populations. 9 Trials of dual antiplatelet therapy (eg, adding clopidogrel 10 or cilostazol 11 to aspirin) and triple antiplatelet therapy (adding clopidogrel and dipyridamole to aspirin 12 ) are ongoing in other populations, and trials of a potent selective protease-activated receptor-4 (PAR4) antagonist and new direct oral anticoagulants are planned. Future trials should measure the severity, as well as the incidence, cause, and timing of recurrent vascular events. In The Lancet, Fiona J Charlson and colleagues 1 use data from the Global Burden of Disease Study 2013 to show the substantial disease burden associated with mental, neurological, and substance use disorders, as well as the probable health service and workforce challenges that will continue to emerge in the coming decades for both China and India. According to their new analysis, the two most populous nations in the world, India and China, account for 32% of the disease burden of global mental, neurological, and substance use disorders, which is greater than that in all developed countries combined. China accounts for 17% and India accounts for 15%, with depressive disorders and anxiety disorders being the most common.
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The eff ects of mental, neurological, and substance use disorders in these countries extend far beyond the individual. The stigma associated with mental health impacts on employment opportunities and thus material circumstances and the social economic status of the family, compounding social inequities for those with mental, neurological, and substance use disorders. These wider implications have not been addressed in the generally descriptive analysis by Charlson and colleagues, 1 which they acknowledge. Thus, the burden of mental, neurological, and substance use disorders described in China and India is very likely an underestimate of the true eff ect of such disorders in these populations. The analysis also overlooks the likely large regional diff erences in the burden of such disorders across both countries. We know, for example, that there is substantial geographical variation across non-communicable disease outcomes in China generally, 2,3 including suicide, 4 which refl ects the heterogeneity in social, economic, demographic, cultural, and health service factors that are likely determinants of mental health outcomes. More geographically specifi c estimates can provide a detailed understanding of local context, and health and social service needs in addressing the disease burden associated with mental, neurological, and substance use disorders. We also know there are substantial barriers to mental health care in both China and India-most individuals with mental illnesses do not access psychiatric health services. [5] [6] [7] In recent years in China there has been the development of a series of national mental health policy reforms relating to the expansion of acute and communitybased mental health care. [8] [9] [10] The recently implemented national mental health laws in China in 2012 9 are helping to develop capacity in acute and community-based care for severe mental disorders, regulating the diagnosis and treatment of mental disorders, and establishing health institutes and institutional capacity for health professionals in the diagnosis and treatment of mental disorders. The integration of mental health care with community-based services for early detection and treatment and rehabilitation is also prominent in these Reforming mental health in China and India from Bayer for lecturing about stroke prevention in atrial fi brillation at sponsored scientifi c symposia, and from Medscape, Web MD, for participating in a discussion about stroke prevention in atrial fi brillation for theheart.org.
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